Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2818286 | 0.83 | PARP1 (0.45) | ANPEPHPGDKDM4EALDH1A1GAA | |
| SCHEMBL166123 | 0.82 | HPGD (0.47) | ANPEPDPP4HPGDKDM4EALDH1A1 | |
| SCHEMBL2820121 | 0.79 | HPGD (0.45) | ANPEPDPP4HPGDKDM4EALDH1A1 | |
| SCHEMBL2820310 | 0.78 | SMN1; SMN2 (0.44) | HPGDKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL22525287 | 0.76 | CASP3 (0.52) | ANPEPDPP4HPGDKDM4EALDH1A1 | |
| SCHEMBL29779636 | 0.73 | MAOA (0.56) | HPGDKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL51539 | 0.73 | MAOA (0.56) | HPGDKDM4EALDH1A1GAAHSD17B10 | |
| SCHEMBL2824441 | 0.72 | KDM4E (0.49) | ANPEPDPP4HPGDKDM4EALDH1A1 | |
| SCHEMBL22525903 | 0.72 | CASP3 (0.52) | ANPEPDPP4HPGDKDM4EALDH1A1 | |
| SCHEMBL9051179 | 0.72 | PTGS2 (0.47) | HPGDBLMMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024233683-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | ALUME BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240124523-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-18 | — | — | US | disclosed |
| US-20240091387-A1 | METHODS AND SYSTEMS USING PEPTIDES FOR TARGETING AND MAPPING HUMAN NERVES IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | ALUME BIOSCIENCES INC (US) | 2024-03-21 | — | — | US | disclosed |
| CN-111246873-B | Optimized peptides for targeting human nerves and their use in image guided surgery, diagnosis and therapy delivery | 加利福尼亚大学董事会 | 2024-03-01 | — | — | CN | disclosed |
| WO-2011049960-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010121023-A2 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | CHARLESSON, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTONOMY, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | OTONOMY, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | BRIGHAM AND WOMEN"S HOSPITAL (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1487471-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS AND REAGENTS RELATED THERETO | Trustees of Tufts College (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003045228-A9 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TUFTS COLLEGE (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003045228-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016218-A1 | CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS | BAX, BCL2, AIFM1 | ANPEP 2602/4885DPP4 3841/4885HPGD 1184/4885 |
| US-20100247659-A1 | PHENYLPHTHALIMIDE ANALOGS FOR TREATING DIABETIC MACULAR EDEMA | SLC2A8, VEGFA, SLC2A1 | ANPEP 363/4885DPP4 35/4885HPGD 1315/4885 |
| US-20100022661-A1 | CONTROLLED RELEASE COMPOSITIONS FOR MODULATING FREE-RADICAL INDUCED DAMAGE AND METHODS OF USE THEREOF | OTC, ARG2, COX6A1 | ANPEP 3256/4885DPP4 3309/4885HPGD 157/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | ANPEP 95/4885DPP4 869/4885HPGD 2644/4885 |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | DNPEP, PREP, VIP | ANPEP 21/4885DPP4 11/4885HPGD 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.